March 7, 2023 News by Lindsey Shapiro, PhD ACTRIMS 2023: GA Depot found to ease MS disability in Phase 3 trial GA Depot, an experimental long-acting version of glatiramer acetate, significantly reduced relapse rates and prevented the development of new lesions among people with relapsing forms of multiple sclerosis, according to new data from a Phase 3 clinical…
March 7, 2023 News by Lindsey Shapiro, PhD ACTRIMS 2023: RRMS treatment may ‘give patients a better choice’ New data from a Phase 2 clinical trial testing vidofludimus calcium, Immunic Therapeutics’ novel oral treatment candidate for relapsing-remitting multiple sclerosis (RRMS), show promising safety and efficacy, according to the company’s chief medical officer. The therapy was…
March 6, 2023 News by Marisa Wexler, MS ACTRIMS 2023: Can Do MS brings education, connection, activation Can Do MS has three missions for people with multiple sclerosis (MS) and their care partners — providing education about life with the disease, building connections among people, and activating them to be proactive about managing their…
March 6, 2023 News by Marisa Wexler, MS ACTRIMS 2023: Delays in Ocrevus infusions not tied to greater MS activity People with multiple sclerosis (MS) being treated with Ocrevus (ocrelizumab) less frequently than the recommended every six months are not more likely to experience inflammatory disease activity, an analysis of some 360 patients whose dosing schedules changed…
March 3, 2023 Columns by Jennifer (Jenn) Powell ACTRIMS 2023: Learning, lectures, and leaving with hope Even the cold and rainy Southern California weather did little to dampen the excitement of the more than 1,800 attendees converging on the Marriott Marquis San Diego Marina. People filtered in, eager for the meeting to begin. Excitement reached…
March 3, 2023 News by Marisa Wexler, MS ACTRIMS 2023: TG aims to make Briumvi accessible to patients Briumvi (ublituximab-xiiy) recently became the third anti-CD20 monoclonal antibody to be approved by the U.S. Food and Drug Administration (FDA) as a treatment for relapsing forms of multiple sclerosis (MS). TG Therapeutics, the therapy’s developer, is…
March 3, 2023 News by Marisa Wexler, MS ACTRIMS 2023: Ibudilast did not lift life quality in progressive MS trial Treatment with the experimental oral therapy ibudilast (MN-166) does not significantly improve quality-of-life measures compared with a placebo among people with progressive forms of multiple sclerosis (MS), according to new data from a Phase 2 clinical trial.
March 3, 2023 News by Marisa Wexler, MS ACTRIMS 2023: High-dose vitamin D doesn’t reduce MS activity: Trial Taking high-dose vitamin D supplements as an add-on to standard MS treatment doesn’t reduce the risk of inflammatory disease activity for people with relapsing-remitting multiple sclerosis (RRMS), according to data from a clinical trial. The findings…
March 2, 2023 News by Marisa Wexler, MS ACTRIMS 2023: Certain eye cells tied to MS-related changes in study Certain cells in the eyes — specifically blood vessel cells and a type of neurological immune cell called microglia — exhibit high expression or activity of genes that have been linked to multiple sclerosis…
March 2, 2023 News by Lindsey Shapiro, PhD ACTRIMS 2023: Documentary offers hope for the Black MS community Multiple sclerosis (MS) has long been considered a disease that mostly affects white women. But in the U.S., the numbers indicate that Black people, particularly Black women, may be more likely to develop the neurodegenerative disease than people…